Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02306993 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sickle Cell Hemoglobinopathies and Bone Health

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 10 months later Dec 2025 → Nov 2028
See other at-risk trials from UConn Health

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 2025 to Nov 2028v12
  2. Minor Site details revisedv11
  3. Minor Re-verified, no change to tracked fieldsv10
  4. Notable Primary completion date: Dec 2023 to Dec 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2024 to Dec 2025
    • Site details revised
    v9
  5. Notable Primary completion date: Dec 2019 to Dec 2023
    • Study completion date: Dec 2020 to Dec 2024
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Primary completion date: Dec 2018 to Dec 2019
    • Study completion date: Dec 2019 to Dec 2020
    v7
  2. Notable Primary completion date: Dec 2017 to Dec 2018
    • Study completion date: Dec 2017 to Dec 2019
    v6
  3. Minor Primary and study completion dates: Jun 2017 to Dec 2017v5
  4. Minor Primary and study completion dates: May 2017 to Jun 2017
    • Study site revised
    v4
  5. Minor Re-verified, no change to tracked fieldsv3
  6. Minor Site contact updatedv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. African Americans are less likely to develop thin bones than whites, but if they sustain a bone fracture, they are more likely to die from it. We believe having sickle cell trait may lead to bone thinning and predispose a subset of African Americans to dangerously thin bones. The second purpose is to try to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do. Doctors have already discovered that people with sickle cell disease have very thin bones, but they have not determined why. Our study will try to identify whether the bone thinning is from the body not making enough bone or from the body losing bone once it is made.
Trial Details
NCT Number NCT02306993
Lead Sponsor UConn Health
Conditions
(from sponsor)
Sickle Cell Disease, Sickle Cell Trait
Related terms Anemia, Sickle Cell, Sickle Cell Trait
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov